Atara Biotherapeutics, Inc. (LON:0HIY)
11.92
-0.13 (-1.07%)
At close: Sep 12, 2025
Atara Biotherapeutics Revenue
Atara Biotherapeutics had revenue of $17.58M USD in the quarter ending June 30, 2025, a decrease of -38.63%. This brings the company's revenue in the last twelve months to $188.67M, up 202.41% year-over-year. In the year 2024, Atara Biotherapeutics had annual revenue of $128.94M with 1,404.02% growth.
Revenue (ttm)
$188.67M
Revenue Growth
+202.41%
P/S Ratio
0.43
Revenue / Employee
$1.23M
Employees
153
Market Cap
59.58M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 128.94M | 120.37M | 1,404.02% |
Dec 31, 2023 | 8.57M | -55.00M | -86.51% |
Dec 31, 2022 | 63.57M | 43.23M | 212.55% |
Dec 31, 2021 | 20.34M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Atara Biotherapeutics News
- 5 weeks ago - Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress - Business Wire
- 2 months ago - Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PRNewsWire
- 2 months ago - Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease - Business Wire
- 2 months ago - Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. - PRNewsWire
- 2 months ago - Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®) - Business Wire
- 4 months ago - Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors - Business Wire
- 4 months ago - Atara Biotherapeutics GAAP EPS of $3.50, revenue of $98.15M - Seeking Alpha
- 4 months ago - Atara Biotherapeutics prices $16M public offering - Seeking Alpha